基因与疾病（英文）2025，Vol.12Issue(3)：137-145,9.DOI:10.1016/j.gendis.2024.101372
Transcription factors,metabolic dysfunction-associated fatty liver disease,and therapeutic implications
Transcription factors,metabolic dysfunction-associated fatty liver disease,and therapeutic implications
Shuwei Hu 1Yingjie Ai 2Checheng Hu 3Fathima N.Cassim Bawa 4Yanyong Xu5
作者信息
- 1. Department of Integrative Medical Sciences,Northeast Ohio Medical University,Rootstown,OH 44272,USA
- 2. Department of Pathology of School of Basic Medical Sciences,Department of Gastroenterology and Hepatology of Zhongshan Hospital,Fudan University,Shanghai 200032,China
- 3. Department of Pathology of School of Basic Medical Sciences,Fudan University,Shanghai 200032,China
- 4. Institute of Diabetes,Obesity and Metabolism,Department of Medicine,University of Pennsylvania Perelman School of Medicine,Philadelphia,PA 19104,USA
- 5. Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education,Frontier Innovation Center,Department of Pathology of School of Basic Medical Sciences,Fudan University,Shanghai 200032,China
- 折叠
摘要
关键词
Apoptosis/Fibrosis/Inflammation/MAFLD/Steatosis/Transcription factorsKey words
Apoptosis/Fibrosis/Inflammation/MAFLD/Steatosis/Transcription factors引用本文复制引用
Shuwei Hu,Yingjie Ai,Checheng Hu,Fathima N.Cassim Bawa,Yanyong Xu..Transcription factors,metabolic dysfunction-associated fatty liver disease,and therapeutic implications[J].基因与疾病（英文）,2025,12(3):137-145,9.基金项目
This work was supported by the National Natural Science Foundation of China(No.32271218 to Y.X.). （No.32271218 to Y.X.）
